Kevin M. Brennan - Oct 1, 2024 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
SVP, FINANCE AND ACCOUNTING
Signature
/s/ Julia Walcott, Attorney-in-Fact
Stock symbol
XLO
Transactions as of
Oct 1, 2024
Transactions value $
$0
Form type
4
Date filed
10/2/2024, 05:15 PM
Previous filing
May 3, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLO Stock Option (right to buy) Award $0 +26K $0.00 26K Oct 1, 2024 Common Stock 26K $0.75 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option was granted on October 1, 2024 and will vest as to 100% of the shares underlying the option on September 30, 2025, subject to the Reporting Person's continued service to the Issuer or its subsidiaries through the vesting date.